Institute of TCM Clinical Basic Medicine, College of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Epilepsy Center, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, Zhejiang, China.
Inflammopharmacology. 2019 Jun;27(3):511-520. doi: 10.1007/s10787-019-00587-4. Epub 2019 Mar 25.
To investigate whether glucocorticoids, the hallmark medication for systemic lupus erythematosus (SLE), could prevent the development of neuropsychiatric SLE (NPSLE).
The protective effects of prednisone on NPSLE were tested using the open field, object recognition/placement, forced swim, tail suspension, and sucrose preference tests in MRL/lpr mice. Auto-antibody titres and the weight of lymph nodes were also measured.
MRL/lpr mice exhibited mild depression at the age of 8 weeks before progressing with spatial cognitive impairment and severe depression-like behaviour at the age of 16 weeks. Treating MRL/lpr mice with prednisone (5 mg/kg) from the age of 8 weeks decreased anti-cardiolipin and anti-N-methyl-D-aspartate (NMDA) receptor antibody titres in the brain, reduced the weight of lymph nodes, and prolonged the floating latency in the forced swim test. However, prednisone (3 or 5 mg/kg) had no preventive effect on the development of spatial cognitive impairment and other depression-like behaviours in MRL/lpr mice. The dose of prednisone had a positive correlation with the floating latency in the forced swim test, while it offered no effects on all other behavioural tests.
Our results provide evidence that early treatment with prednisone had a limited effect on the development of neuropsychiatric symptoms in MRL/lpr mice. Further work is needed in other models beyond NPSLE in MRL/lpr mice before any definitive conclusions are made on the efficacy of prednisone in human NPSLE.
研究糖皮质激素(系统性红斑狼疮(SLE)的标志性药物)是否可预防神经精神性 SLE(NPSLE)的发生。
采用旷场实验、物体识别/放置实验、强迫游泳实验、悬尾实验和蔗糖偏好实验,测试泼尼松对 MRL/lpr 小鼠 NPSLE 的保护作用。还测量了自身抗体滴度和淋巴结重量。
MRL/lpr 小鼠在 8 周龄时出现轻度抑郁,16 周龄时出现空间认知障碍和严重的抑郁样行为。从 8 周龄开始用泼尼松(5mg/kg)治疗 MRL/lpr 小鼠可降低脑内抗心磷脂和抗 N-甲基-D-天冬氨酸(NMDA)受体抗体滴度,减轻淋巴结重量,并延长强迫游泳实验中的漂浮潜伏期。然而,泼尼松(3 或 5mg/kg)对 MRL/lpr 小鼠空间认知障碍和其他抑郁样行为的发展无预防作用。泼尼松的剂量与强迫游泳实验中的漂浮潜伏期呈正相关,而对所有其他行为测试均无影响。
我们的结果表明,早期用泼尼松治疗对 MRL/lpr 小鼠神经精神症状的发展仅有有限的作用。在对 MRL/lpr 小鼠的 NPSLE 以外的其他模型进行进一步研究之前,不能对泼尼松在人类 NPSLE 中的疗效作出任何明确的结论。